Ely Benaim is Chief Medical Officer at NovoCure Ltd (NVCR). They have made 17 open-market trades across 1 company since 2020, most recently 2023-01-06.
CIK 0001632237
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 17 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVCR | SELL | 2022-08-03 | 2022-08-04 | $73.73 | $439K | +13.6% | +8.4% | -2.4% |
| NVCR | SELL | 2022-08-02 | 2022-08-03 | $69.66 | $30K | +16.0% | +8.2% | +0.7% |
| NVCR | SELL | 2022-05-10 | 2022-05-12 | $63.17 | $531K | +20.0% | +2.0% | +30.2% |
| NVCR | SELL | 2022-03-03 | 2022-03-07 | $71.83 | $332K | +12.5% | +25.0% | +15.6% |
| NVCR | SELL | 2021-08-03 | 2021-08-04 | $150.11 | $139K | -10.7% | -9.0% | -29.3% |
| NVCR | SELL | 2021-07-30 | 2021-08-03 | $154.63 | $367K | -6.3% | -5.6% | -27.4% |
| NVCR | SELL | 2021-05-27 | 2021-05-28 | $200.00 | $367K | +6.1% | +8.7% | -35.0% |
| NVCR | SELL | 2021-05-12 | 2021-05-14 | $180.48 | $701K | +6.7% | +23.9% | -20.0% |
| NVCR | SELL | 2021-05-10 | 2021-05-12 | $184.39 | $1.5M | +1.9% | +18.9% | -21.8% |
| NVCR | SELL | 2021-04-13 | 2021-04-15 | $200.00 | $1.2M | +8.8% | -10.4% | -5.5% |
| NVCR | SELL | 2021-03-05 | 2021-03-09 | $131.53 | $768K | +5.7% | -1.1% | +56.3% |
| NVCR | SELL | 2021-03-03 | 2021-03-05 | $146.12 | $1.6M | +13.6% | +2.1% | +60.5% |
| NVCR | SELL | 2020-12-21 | 2020-12-22 | $156.71 | $779K | -4.4% | +1.1% | -17.5% |
| NVCR | SELL | 2020-08-03 | 2020-08-05 | $76.06 | $100K | -1.7% | +2.6% | +46.0% |
| NVCR | SELL | 2020-07-31 | 2020-08-03 | $76.39 | $26K | -0.9% | +10.4% | +46.0% |
| NVCR | SELL | 2020-05-12 | 2020-05-14 | $64.78 | $336K | +7.7% | +5.4% | +21.0% |
| NVCR | SELL | 2020-05-11 | 2020-05-12 | $63.73 | $205K | +5.1% | +3.6% | +24.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.